Abstract
New insight on the interaction between the immune system and tumor has identified the programmed death-1/programmed death-1 ligand pathway to be a key player in evading host immune response. The immune checkpoint modulator, nivolumab (BMS-936558/ONO-4538), is the first PD-1 inhibitor to gain regulatory approval, for the treatment of patients with unresectable melanoma. This review will discuss results from early phase studies of nivolumab in solid tumors including non-small cell lung cancer (NSCLC) as well as studies of nivolumab in combination with chemotherapy, other immune modulators and molecular targeted therapy in patients with NSCLC.
Original language | English |
---|---|
Pages (from-to) | 85-96 |
Number of pages | 12 |
Journal | Therapeutic Advances in Medical Oncology |
Volume | 7 |
Issue number | 2 |
DOIs | |
Publication status | Published - 2015 Mar |
Bibliographical note
Funding Information:RS, BCC and RAS have no conflicts of interest to declare. JBR has received research funding from Merck and BMS, is a paid consultant for Merck and is a compensated advisory board member for BMS.
Funding Information:
RAS is supported by the National Research Foundation, Singapore and the Singapore Ministry of Education under its Research Centres of Excellence initiative.
All Science Journal Classification (ASJC) codes
- Oncology